Methotrexate is an antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.
Methotrexate is approved by the Food and Drug Administration (FDA) to be used by itself to treat the following types of gestational trophoblastic tumors, Chorioadenoma destruens, Choriocarcinoma, Hydatidiform mole. Methotrexate is also approved to be used alone or with other drugs to treat acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to keep it from spreading there, and to treat the following, breast cancer, certain types of head and neck cancer, lung cancer, advanced non-Hodgkin lymphoma (NHL), advanced mycosis fungoides (a type of cutaneous T-cell lymphoma), osteosarcoma that has not spread to other parts of the body, following surgery to remove the primary tumor. Methotrexate is also approved to treat the following non-cancer conditions, rheumatoid arthritis, severe psoriasis.
A UCLA study has outlined a new framework that researchers say would improve predictive power of genetics to determine how well a patient would respond to commonly prescribed medications as well as the severity of any side effects.
Scientists have uncovered amazing information about the role of an enzyme that could assist in the development of drugs for aggressive cancers in just two neutron experiments.
The various chemical proteomics methods with relevant examples.
The existing knowledge on monolayers and spheroid-based cell cultures, including the constituent compounds, and the difference in efficacy during drug screening, especially for anti-cancer drugs targeting cytoskeletal dynamics and cell cycles.
Two anti-inflammatory drugs, abatacept and infliximab, reduced deaths among patients hospitalized with severe COVID-19, according to a national study led by Washington University School of Medicine in St. Louis.
The effectiveness of a novel nano molecule as a drug delivery system has been examined in a recent study by the University of Barcelona.
A metabolic enzyme that has been studied in cancer biology and is important for T cell function may offer a new target for anti-inflammatory therapeutics, Vanderbilt researchers have discovered.
A research team from Italy has discovered a pair of microRNA molecules that assist in maintaining a population of cancerous stem cells that fuel the growth of breast cancers and trigger tumor relapse after treatment.
Cancer is one of the world's greatest health afflictions because, unlike some diseases, it is a moving target, constantly evolving to evade and resist treatment.
There is a wide range of mechanisms related to chemoresistance, a majority of which are yet to be fully understood.
Researchers from the University of Groningen have visualized the characteristics of a single enzyme within a nanopore.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.